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Abstract
Background: This study aimed to inform the design of a pragmatic trial of stroke prevention in primary care by
evaluating data recorded in electronic patient records (EPRs) as potential outcome measures. The study also
evaluated achievement of recommended standards of care; variation between family practices; and changes in risk
factor values from before to after stroke.
Methods: Data from the UK General Practice Research Database (GPRD) were analysed for 22,730 participants with
an index first stroke between 2003 and 2006 from 414 family practices. For each subject, the EPR was evaluated for
the 12 months before and after stroke. Measures relevant to stroke secondary prevention were analysed including
blood pressure (BP), cholesterol, smoking, alcohol use, body mass index (BMI), atrial fibrillation, utilisation of
antihypertensive, antiplatelet and cholesterol lowering drugs. Intraclass correlation coefficients (ICC) were estimated
by family practice. Random effects models were fitted to evaluate changes in risk factor values over time.
Results: In the 12 months following stroke, BP was recorded for 90%, cholesterol for 70% and body mass index
(BMI) for 47%. ICCs by family practice ranged from 0.02 for BP and BMI to 0.05 for LDL and HDL cholesterol. For
subjects with records available both before and after stroke, the mean reductions from before to after stroke were:
mean systolic BP, 6.02 mm Hg; diastolic BP, 2.78 mm Hg; total cholesterol, 0.60 mmol/l; BMI, 0.34 Kg/m2. There was
an absolute reduction in smokers of 5% and heavy drinkers of 4%. The proportion of stroke patients within the
recommended guidelines varied from less than a third (29%) for systolic BP, just over half for BMI (54%), and over
90% (92%) on alcohol consumption.
Conclusions: Electronic patient records have potential for evaluation of outcomes in pragmatic trials of stroke
secondary prevention. Stroke prevention interventions in primary care remain suboptimal but important reductions
in vascular risk factor values were observed following stroke. Better recording of lifestyle factors in the GPRD has
the potential to expand the scope of the GPRD for health care research and practice.
Background
Individuals who survive stroke are at increased risk of
recurrent stroke [1]. The risk of recurrence is highest
during the first year following a stroke but remains ele-
vated for at least 10 years [2,3]. Clinical practice recom-
mendations for secondary prevention of stroke,
including the UK Intercollegiate Stroke Working Party
(ICSWP) guidelines [4] and the American Heart Asso-
ciation (AHA) guidelines, [5] emphasise the requirement
to intervene to reduce the risk of further strokes, and
other cardiovascular events, by targeting major modifi-
able vascular risk factors including elevated blood pres-
sure (BP), and high cholesterol levels, as well as
implementing antiplatelet therapy and lifestyle change
when appropriate. These recommendations draw on evi-
dence from meta-analyses of randomised controlled
trials and other studies that provide evidence of the pro-
tective role of antiplatelet, cholesterol lowering and anti-
hypertensive therapy against the risk of recurrent
strokes and other vascular events [6-12].
Few nationally representative, population-based studies
of stroke secondary prevention, and changes in vascular
risk factor values following stroke, have been reported.
* Correspondence: alexandru.dregan@kcl.ac.uk
† Contributed equally
1Division of Health and Social Care Research, King’s College London, Capital
House, Weston Street, London, UK
Full list of author information is available at the end of the article
Dregan et al. BMC Public Health 2011, 11:86
http://www.biomedcentral.com/1471-2458/11/86
© 2011 Dregan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The present study therefore aimed to evaluate the imple-
mentation of stroke secondary prevention in primary
care by using electronic patient records (EPR) from a
large population. The analyses had the additional purpose
of informing the design of a cluster randomised trial of
computerised decision support. The development of the
intervention for the study has been reported elsewhere
[13]. The reported analyses therefore explored the feasi-
bility of using data from EPRs to evaluate outcome mea-
sures for intervention trials of stroke prevention.
Methods
Participants
Data for this study were derived from the UK General
Practice Research Database (GPRD). The GPRD is a
large database that contains electronic patient records
from over 400 family practices in the UK. The geo-
graphic distribution and demographic profile of the
GPRD are representative of the UK population [14]. The
validity of medical diagnoses and prescribing informa-
tion in GPRD has been confirmed in several studies
[15]. In the GPRD, data are designated as ‘up-to-
standard’ (UTS) when they are judged to be of high
enough quality to be used for research.
Data for the present analyses were extracted from the
records of 414 UK general practices with a registered
population of approximately 3.2 million in 2006. The
initial sample comprised 48,239 participants. The last data
were collected in August 2007. Stroke patients were iden-
tified using the 202 READ and OXMIS codes for stroke
that were described previously [16,17]. Transient ischemic
attacks were not included. A first stroke was defined as a
first diagnosis of stroke during the period 01/01/1997-31/
12/2006 inclusive with a minimum of 24 months of up-to-
standard record free from stroke codes preceding the
index event. This ensured that all stroke patients represent
new diagnoses. Incidence and case-fatality rates for stroke
in GPRD appear to be comparable to estimates obtained
from other epidemiological studies [17].
For the present analyses, only those individuals for
whom a first stroke event was recorded between 1st Jan-
uary 2003 and 31st December 2006 were retained
because these represented recent years’ data with
improved quality data recording and greater relevance
to contemporary clinical practice. Data for 64 individuals
with stroke diagnoses first recorded after the death date
were excluded. The final study sample comprised
21,330 participants with a first stroke event between 1st
January 2003 and 31st December 2006. The mean age
of the participants was 73 years and 53% were women.
Data for analysis
The electronic patient record was evaluated for each
subject for the 12 months preceding, and for the
12 months after, the stroke index date. The stroke index
date was defined as the first date on which a stroke med-
ical code was recorded. Data were analysed for six con-
tinuous variables: systolic blood pressure (BP; mm Hg);
diastolic BP (mm Hg); total cholesterol (mmol/l);
low density lipoprotein (LDL) cholesterol (mmol/L); high
density lipoprotein (HDL) cholesterol (mmol/L); and
body mass index (BMI; Kg/m2). For each of the continu-
ous measures, the mean of all values recorded in each
participant in the 12 months before, or after, stroke was
estimated.
Electronic patient records were also evaluated for a
further ten dichotomous outcomes including whether:
the blood pressure was recorded; antihypertensive drugs
were prescribed; cholesterol was measured (including
total, LDL or HDL cholesterol); statins were prescribed;
atrial fibrillation was recorded; antiplatelet drugs were
prescribed; whether anticoagulants were prescribed;
whether the body mass index was recorded; whether
smoking or alcohol habits were recorded. These out-
comes were extracted from the clinical, referral and
therapy files using READ medical codes or BNF formu-
lary codes.
Recording of blood pressure, cholesterol, atrial fibrilla-
tion, and body mass index (BMI) were characterised by
whether or not one or more measurements were
recorded in either the year before or the year after
stroke. Drug prescriptions were analysed in the same
way. Antihypertensive drugs included ACE inhibitors,
angiotensin-II receptors, calcium-channel blockers,
centrally acting antihypertensive drugs, diuretics, beta--
blockers, and adrenergic neurone blocking drugs. Anti-
platelet drugs included aspirin and dipyridamole.
Anticoagulants included oral (e.g. warfarin) anticoagu-
lants and just a small number of parenteral (e.g.
heparin) anticoagulant prescriptions. Information con-
cerning smoking included whether the participant’s
smoking habit was recorded, as well as whether the indi-
vidual was recorded as a current smoker in the
12 months. Information concerning alcohol included
whether the alcohol intake was recorded, and whether
alcohol intake was higher than recommended limits.
Recommended upper limits were 21 units per week for
men and 14 units per week for women.
Statistical analysis
For binary outcomes, because of right censoring follow-
ing stroke arising from early mortality, a series of
time-to-event analyses were implemented to estimate
the proportion of stroke participants with the outcomes
of interest during the 12 months following the stroke
index date. For continuous measures, the study investi-
gated the mean values for systolic and diastolic blood
pressure, cholesterol levels (total, LDL, and HDL), and
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BMI values in the 12 months before and after the stroke
index date. For each measure, the participant-specific
mean was estimated by stroke index year. For lifestyle
measures, the study estimated the proportion of stroke
participants that, at any time during the 12 months
before or after the stroke index date, were recorded as
current smokers or consuming over the recommended
units of alcohol per week. For participants with outcome
data available both before and after the stroke index
date, a random-effects model FOR REPEATED MEA-
SURES, with participant as the random effect, was used
to estimate gender and age adjusted differences (and
associated confidence intervals). For the binary measures
(smoking and alcohol) a two-sample proportion test was
used to examine differences (and associated confidence
intervals) in the proportions before and after stroke.
Additional analyses were carried out to explore the
variation in the distribution of outcome measures at
different family practices. The intraclass correlation
coefficient (ICC) by family practice was calculated using
one-way ANOVA for the continuous outcome mea-
sures: systolic and diastolic blood pressure, cholesterol,
and BMI index. All analyses were carried out using
STATA version 11.
Ethics
The study was implemented utilising an anonymised
dataset from the General Practice Research Database.
The study protocol was approved by the Independent
Scientific Advisory Committee (ISAC) of the Medicines
and Healthcare products Regulatory Agency (MHRA)
(ISAC Protocol No. 07_027R).
Results
In the 4-year study period from 1st January 2003 to 31st
December 2006, a total of 22,730 first-ever stroke diag-
noses were recorded in the GPRD. The frequency of
records of blood pressure, cholesterol, BMI, and lifestyle
factors are presented in Table 1. Risk factor recording
was more frequent after stroke than before. In the
12 months following stroke, BP was recorded for 90%,
cholesterol for 70%, BMI for 47% and smoking and alco-
hol habits for 73% and 35% respectively. Risk factor
management was greater after stroke than before, and
generally increased over time, with between two thirds
and three quarters of patients being treated with antihy-
pertensive drugs or statins. A smaller proportion (7%) of
patients had a record of anticoagulant prescription in
the 12 months before the stroke index date which
increased to12%in the 12 months after the stroke index
date. Low anticoagulant prescriptions appeared to be
consistent with the small proportion of patients
recorded as having atrial fibrillation in the period.
A third (33%) of patients with atrial fibrillation were
treated with anticoagulants in the 12 months before the
stroke index date compared to 55% in the 12 months
after the stroke index date.
Table 2 describes substantial variation in adherence to
stroke secondary prevention recommendations among
family practices. In general the proportion of patients
with measures recorded ranged from 0 to 100% at dif-
ferent practices. Mean values for continuous measures
and intraclass correlation coefficients for the main out-
come measures by family practice are presented in
Table 3. The intraclass correlation coefficient for the
systolic BP in the 12 months before stroke was 0.02 and
0.03 in the 12 months after stroke. For diastolic BP, the
intraclass correlation coefficient was 0.03, and for both
BMI and total cholesterol 0.02, both before and after
stroke. A higher intraclass correlation coefficient of
0.05 was observed for both LDL and HDL cholesterol
both before and after stroke.
Table 4 presents the results based on patients who
were selected because their records provided information
both before and after the stroke event. There were quan-
titatively important reductions from before- to after-
stroke in systolic and diastolic blood pressure as well as
total and LDL cholesterol, BMI, current smoking and
excessive drinking. Systolic BP was 6mm Hg lower after
stroke than before, total cholesterol was 0.6 mmol/l
lower after stroke than before, LDL cholesterol was
0.7 mmol/l lower, BMI was 0.3 kg/m2 lower, and there
was a reduction in the proportion of active smokers of
5% and excessive drinkers of 4%. There was also evidence
of a declining secular trend in values for systolic and
diastolic blood pressure, as well as for total and LDL
cholesterol. Tests for trend gave P values of 0.004 or
smaller for each of these measures either before or after
stroke.
Table 5 presents the proportion of patients who
achieved recommended target values for the measures
analysed. For each measure, the denominator was the
total with the item recorded. Between one quarter to a
third of patients achieved systolic BP target, but the pro-
portion was almost two-thirds for diastolic BP. Just
under a half of patients achieved total cholesterol targets
while just over half of stroke patients achieved LDL cho-
lesterol targets. A similar finding emerged with respect
to BMI values. More encouraging results emerged with
respect to HDL cholesterol, smoking, and alcohol units
per week where less than a tenth to around a fifth of




The present results show that electronic patient records
from primary care provide a valuable tool for evaluating
vascular risk factor values including blood pressure,
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cholesterol, BMI and smoking. Data on drug prescrip-
tions provide the opportunity to assess adherence with
guidelines in secondary stroke prevention. The data pre-
sented may be used to inform the design of stroke pre-
vention studies in primary care.
This study represents one of the first primary care-
based stroke studies to compare risk factor values from
before to after stroke. Among participants with values
available both before and after stroke, there were clini-
cally important overall reductions in blood pressure,
cholesterol, BMI, cigarette smoking and excessive drink-
ing from before to after stroke. These differences
appeared to diminish slightly over time, possibly as a
result of a declining secular trend in pre-stroke risk fac-
tor values. Reductions in BMI may be favourable but
might sometimes be a sign of impaired nutrition after
stroke. Increased prescribing of antihypertensive drugs,
statins after stroke may have contributed to observed
reductions in blood pressure and cholesterol values.
These might potentially translate into better outcomes
for stroke patients, including survival and reduced
recurrence rates [8,10,11]. The substantial variation in
drug prescriptions at a practice level reinforce previous
findings [18] and extend these findings to GP consulta-
tions. Several explanations may be offered for the
observed between-practice variation including practi-
tioner-level factors, including the acceptability of guide-
lines, and practice-level factors including practice
management and the practice population. These sugges-
tions could not be tested here but need considering
when designing cluster-level interventions to improve
adherence to recommended guidelines.
Table 1 Primary care management in the 12 months before and after stroke by year of stroke
2003 2004 2005 2006 Total
(N = 5,334) (N = 6,248) (N = 5,764) (N = 5,384) (N = 22,730)
BP record Before stroke 3,453 (70%) 4,539 (77%) 4,320 (80%) 4,137 (81%) 16,449 (77%)
After strokea 3,813 (88%) 5,026 (93%) 4,602 (93%) 4,183 (87%) 17,624 (90%)
Antihypertensive drugs prescribed Before stroke 2,798 (57%) 3,544 (60%) 3,358 (62%) 3,167 (62%) 12,867 (60%)
After stroke a 3,118 (69%) 3,891 (71%) 3,677 (73%) 3,464 (72%) 14,150 (71%)
Antiplatelet drugs Before stroke 1,920 (39%) 2,600 (44%) 2,475 (46%) 2,321 (46%) 9,316 (44%)
prescribed After stroke a 2,865 (64%) 3,546 (65%) 3,301 (65%) 3,074 (64%) 12,786 (65%)
Anticoagulants Before stroke 270 (6%) 364 (6%) 402 (7%) 355 (7%) 1,391 (7%)
prescribed After stroke a 444 (10%) 603 (11%) 627 (13%) 557 (12%) 2,231 (12%)
Atrial fibrillation Before stroke 139 (3%) 179 (3%) 185 (3%) 187 (4%) 690 (3%)
After stroke a 238 (5%) 285 (5%) 265 (5%) 267 (6%) 1055 (5%)
Cholesterol recording (Total, LDL or HDL) Before stroke 1,724 (35%) 2,828 (48%) 2,970 (55%) 2,833 (56%) 10,355 (49%)
After stroke a 2,691 (64%) 3,955 (76%) 3,681 (76%) 2,921 (62%) 13,248 (70%)
Statin prescription Before stroke 1,042 (21%) 1,799 (31%) 1,941 (36%) 2,038 (40%) 6,820 (32%)
After stroke a 2,499 (56%) 3,554 (65%) 3,485 (69%) 3,433 (71%) 12,971 (65%)
BMI record Before stroke 1,391 (28%) 2,050 (35%) 1,953 (36%) 2,042 (40%) 7,436 (35%)
After stroke a 2,249 (39%) 2,417 (48%) 1,959 (54%) 2,353 (46%) 8,978 (47%)
Smoking record Before stroke 1,633 (33%) 3,199 (54%) 3,115 (57%) 2,841 (56%) 10,788 (51%)
After stroke a 2,783 (66%) 4,176 (79%) 3,829 (79%) 3,262 (68%) 14,050 (73%)
Alcohol record Before stroke 972 (20%) 1,596 (27%) 1,343 (25%) 1,3222 (26%) 5,233 (25%)
After stroke a 1,356 (32%) 1,982 (37%) 1,998 (40%) 1,556 (32%) 6,892 (35%)
Figures are frequencies (column percents).
a ’After stroke’ figures are estimated from time-to- event analyses.
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Comparison with earlier studies
The present study findings are consistent with previous
population-based studies that found recent declines in
the proportion of smokers, as well as in mean total
cholesterol levels, and mean systolic and diastolic
blood pressure in stroke patients [19,20]. The study
findings on the proportion of stroke participants trea-
ted with anticoagulants and antiplatelet drugs follow-
ing stroke is consistent with previous studies [3,21-23].
Grau et al. [21] reported that antiplatelet drugs were
administered to 71% of their sample. Rudd et al. [3]
found that 64% of stroke participants had a cholesterol
measure available following stroke with about 63% pre-
scribed a statin. Results for the proportion of partici-
pants on anti-hypertensive treatment are similar to
those reported previously [3,17,22,23]. Given sampling
difference as well as variation in the follow-up period
length between studies may explain modest variations
in figures.
What this study adds
Can data from primary care electronic records inform the
evaluation of stroke secondary prevention in primary care?
The findings of this study suggest that GPRD data repre-
sent potentially a valuable resource to evaluate whether
adherence to recommended stroke prevention guidelines
could improve stroke prognosis. However, this potential
value must be qualified in several respects. Several aspects
of stroke management are specific to stroke subtypes.
However, most strokes are recorded in GPRD using codes
that do not distinguish between haemorrhage and infarc-
tion. More detailed classification of stroke types using
information from CAT or MRI scans is not usually feasi-
ble. A further concern is the low level of recording of life-
style factors recording, in particular obesity, smoking and
alcohol consumption. As a consequence we cannot be
confident that our evaluation of the extent to which the
recommended guidelines regarding these factors is gener-
alisable to other stroke patients. Moreover, the lack of
Table 2 Centiles for family practice-specific proportions (%) of stroke secondary prevention measures
Lowest performing
family practice
Lower quartile Median Upper quartile Highest performing
family practice
BP recorded Before stroke 33 71 77 83 100
After stroke 0 76 82 87 100
Antihypertensive treatment Before stroke 0 67 73 79 100
After stroke 0 77 81 86 100
Antiplatelet treatment Before stroke 0 34 43 50 100
After stroke 0 53 59 65 100
Anticoagulant treatment Before stroke 0 3 6 9 25
After stroke 0 7 10 14 50
Atrial fibrillation Before stroke 0 0 3 5 25
After stroke 0 2 5 7 43
Cholesterol recorded Before stroke 0 38 46 56 100
After stroke 0 53 61 69 88
Statin measure Before stroke 0 23 30 38 100
After stroke 0 53 60 68 100
BMI recorded Before stroke 0 25 33 44 100
After stroke 0 26 37 52 83
Smoking recorded Before stroke 0 41 50 59 100
After stroke 0 55 63 72 100
Alcohol recorded Before stroke 0 14 22 34 100
After stroke 0 12 25 44 80
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additional socio-demographic data places constraints on
the ability to verify that missing data on different outcome
measures is ignorable.
This study provides new evidence on the magnitude of
risk factor reductions during the 12 months following
index stroke. Against a background of declining secular
trends in values for blood pressure and cholesterol, this
study showed that there were important reductions in
blood pressure, cholesterol, body mass index, cigarette
smoking and excessive alcohol drinking from before to
after stroke (2006 data is incomplete because a 6-month
delay in data collection from practices by the GPRD). Epi-
demiologic studies suggest that even modest reductions in
systolic blood pressure of 5-6 mmHg, or diastolic of
2-3mm Hg, may be associated with a 20% to 28% reduced
risk of stroke [24,25]. The reduction in cholesterol observed
is also quantitatively important in the context of evidence
from clinical trials of cholesterol lowering therapy [11].
Reductions in BMI may be regarded favourably but may
also be indicative of nutritional problems following stroke.
Little evidence is available concerning trends in smoking
and alcohol use in stroke populations, but there appear to
be important reductions following stroke. However, the
present results emphasise the need for improved data
recording with respect to these risk factors for stroke
recurrence. This is important considering the potential
value of EPRs for health care research and policy develop-
ment. The study also documents important practice level
variations in the proportion of stroke participants with
records or treatment for several risk factors. The factors
underlying practice level variation could further help the
implementation of the guidelines for secondary stroke pre-
vention, an outcome that will be addressed through our
research.
Limitations of this study
This study had the strength of a large sample drawn
from a large number of family practices from across the
UK. However, several limitations of the data must be
acknowledged. It was not generally possible to distin-
guish sub-types of stroke. Only 17% of strokes could be
classified as either haemorrhages or infarctions. The
stroke type has relevance for certain aspects of second-
ary prevention including the prescriptions of statins,
aspirin and antiplatelet drugs, and anticoagulants. How-
ever, lowering BP has been shown to reduce the risk of
both ischemic and hemorrhagic stroke, while smoking
and alcohol consumption are also associated with risk of
stroke [20,26,27]. Also, while all stroke diagnoses were
recorded prospectively by practices, stroke patients may
be admitted directly to hospital and their first contact
with the practice may be for review at some later date.
The stroke onset date may be therefore imprecisely
recorded in primary care, perhaps often being recorded
after the true stroke date. However, the validity of clini-
cal data included in the GPRD has repeatedly been
shown to be high, and data are rigorously checked and
regularly audited. Another limitation of this research is
the lack of a reference method for stroke diagnosis as
discussed elsewhere [16]. It is also important to
acknowledge that, for an appreciable number of partici-
pants, information about their outcome measures was
not available. The study findings are comparable, how-
ever, to those from previous studies [3,28,29]. Stroke
secondary prevention was evaluated with respect to the
most recent UK guidelines which represent a
2008 update of the 2004 edition. Trends showed some
lack of consistency between 2005 and 2006. This is
probably explained by the shorter duration of follow-up
for some participants with a stroke index date 2006 com-
pared to those with a stroke during previous years.
Conclusions
The present study has documented, in a large nationally
representative sample, that electronic based patient
records represents potentially a valuable source for eval-
uating guidelines implementation with respect to sec-
ondary stroke prevention. The broad nature of the
GPRD data allowed us to identify and operationalise
Table 3 Descriptive statistics and intraclass correlation
coefficient (ICC) by family practice for continuous
measures
N Mean (SD) ICC (SE)
SBP measure
(mmHg)
Before stroke 16,462 144.76 (19.13) 0.020 (0.003)
After stroke 17,626 139.08 (17.05) 0.025 (0.004)
DBP measure
(mmHG)
Before stroke 16,462 80.24 (10.12) 0.028 (0.003)




Before stroke 10,318 5.10 (1.16) 0.018 (0.004)
After stroke 13,210 4.60 (1.06) 0.021 (0.004)
LDL cholesterol
(mmol/l)
Before stroke 5744 2.93 (1.03) 0.047 (0.009)




Before stroke 7,305 1.44 (0.44) 0.045 (0.007)
After stroke 9,182 1.44 (0.44) 0.052 (0.007)
BMI measure
(kg/m2)
Before stroke 6,958 27.21 (5.47) 0.018 (0.005)
After stroke 8,547 26.92 (5.25) 0.016 (0.004)
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Table 5 Proportion of stroke patients with values recorded who were within the range recommended by the
Intercollegiate Stroke Working Party guidelines in the 12 months following a stroke index date
N 2003 2004 2005 2006 Overall
Blood pressure Systolic (< 130 mmHg) 14,006 26% 29% 29% 33% 29%
Diastolic (< 80 mmHg) 14,006 58% 63% 64% 66% 63%
Cholesterol Total (< 4 mmol/l or -25%) 7,085 41% 42% 47% 49% 47%
LDL (< 2 mmol/l or -30%) 3,206 51% 50% 53% 51% 51%
HDL (> 1.00 mmol/l) 4,287 89% 90% 89% 87% 89%
Body Mass Index Weight loss (kg/m2) 3,881 53% 55% 55% 54% 54%
Smoking Non-smokers 7,213 77% 79% 79% 79% 79%
Alcohol units per week Men = < 21;women < 14 1,968 92% 93% 91% 90% 92%
Table 4 Mean values for stroke prevention measures for participants with values recorded both before and after
stroke
2003 2004 2005 2006 Overall
Systolic BP (N = 14,006) Before stroke 148.64 145.72 144.49 143.31 145.54
After stroke 141.60 139.28 139.24 137.78 139.48
Difference( 95% CI) -7.04(-7.69;-6.39) -6.44(-6.97;-5.90) -5.25(-5.79;-4.70) -5.53(-6.10;-4.95) -6.02(-6.03;-6.01)
Diastolic BP (N = 14,006) Before stroke 82.21 80.58 80.17 79.60 80.64
After stroke 78.90 77.70 77.54 77.18 77.83
Difference( 95% CI)** -3.31(-3.66;-2.96) -2.88(-3.18;-2.59) -2.63(-2.93;-2.32) -2.43(-2.75;-2.11) -2.78(-2.79;-2.77)
Total cholesterol (N = 7,085) Before stroke 5.38 5.28 5.09 4.96 5.18
After stroke 4.65 4.52 4.41 4.36 4.49
Difference( 95% CI)** -0.73(-0.79;-0.67) -0.76(-0.80;-0.71) -0.69(-0.73;-0.64) -0.60(-0.65;-0.55) -0.60(-0.61;-0.59)
LDL cholesterol (N = 3,206) Before stroke 3.11 3.12 2.97 2.77 2.99
After stroke 2.44 2.40 2.33 2.30 2.38
Difference( 95% CI)** -0.67(-0.76;-0.57) -0.73(-0.79;-0.66) -0.63(-0.69;-0.57) -0.47(-0.53;-0.40) -0.70(-0.71;-0.69)
HDL cholesterol (N = 4,287) Before stroke 1.40 1.44 1.45 1.44 1.43
After stroke 1.39 1.44 1.44 1.41 1.42
Difference( 95% CI) -0.02(-0.04;0.01) -0.01(-0.02;0.01) -0.01(-0.02;0.00) -0.03(-0.04;-0.02) -0.02(-0.02;-0.01)
BMI values (N = 3,881) Before stroke 27.83 27.86 27.56 27.87 27.78
After stroke 27.52 27.50 27.17 27.58 27.44
Difference( 95% CI) -0.31(-0.45;-0.17) -0.37(-0.48;-0.25) -0.39(-0.51;-0.26) -0.30(-0.41;-0.18) -0.34(-0.34;-0.33)
Current smokers (N = 7,213) Before stroke 31% 26% 24% 27% 26%
After stroke 23% 21% 21% 21% 21%
Difference( 95% CI) -8%(-12%;-4%) -5%(-7%;-2%) -3%(-6%;-1%) -6%(-9%;-3%) -5%(-6%;-3%)
Excessive drinking (n = 1,968) Before stroke 13% 12% 12% 13% 12%
After stroke 8% 7% 9% 10% 8%
Difference( 95% CI) -5%(-10%1%) -5%(-9%;-1%) -3%(-7%1%) -4%(-9%;1%) -4%(-6%;-2%)
Figures are means except where indicated.
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several outcome measures stipulated in the ICSWP as
important targets for secondary stroke prevention. The
study findings indicate a consistent increase in the
screening and treatment of stroke patients over time,
but also the need for further improvement both in
screening and drug prescriptions. The overall message
of the study is that GPRD data is suitable for the imple-
mentation of cluster randomised trials to evaluate the
success or failure of health interventions on stroke
patients’ outcomes.
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